Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 31, 2024 16:01 ET
|
Verve Therapeutics
BOSTON, May 31, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing...
Verve Therapeutics Announces Leadership Update
May 31, 2024 07:00 ET
|
Verve Therapeutics
Troy Lister, Ph.D., to be promoted to chief scientific officer Andrew Bellinger, M.D., Ph.D., will depart the Company and serve in an advisory capacity BOSTON, May 31, 2024 (GLOBE NEWSWIRE) --...
Verve Therapeutics to Participate in Upcoming Investor Conferences
May 30, 2024 16:01 ET
|
Verve Therapeutics
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing...
Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results
May 08, 2024 07:00 ET
|
Verve Therapeutics
First patient dosed in Heart-2 Phase 1b clinical trial of VERVE-102 VERVE-201 clinical trial initiation on track for the second half of 2024 Received first milestone payment from Eli Lilly for...
Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102
May 07, 2024 07:00 ET
|
Verve Therapeutics
VERVE-102 is an investigational in vivo base editing medicine designed to permanently inactivate the PCSK9 gene in the liver to durably reduce blood low-density lipoprotein cholesterol Heart-2...
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 03, 2024 16:01 ET
|
Verve Therapeutics
BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing...
Verve Therapeutics Announces Updates on its PCSK9 Program
April 02, 2024 07:00 ET
|
Verve Therapeutics
Heart-1 clinical trial demonstrated LDL-C reduction of up to 73% at 0.45 mg/kg of VERVE-101 Company to pause enrollment in Heart-1 clinical trial following asymptomatic Grade 3 transient ALT...
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
March 28, 2024 16:51 ET
|
Verve Therapeutics
BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing...
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
March 01, 2024 16:01 ET
|
Verve Therapeutics
BOSTON, March 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing...
Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
February 27, 2024 07:30 ET
|
Verve Therapeutics
Three Clinical Stage Programs Targeting PCSK9 and ANGPTL3 Expected in 2024 Announced First Human Proof-of-Concept Data for In Vivo Base Editing from Ongoing Heart-1 Phase 1b Clinical Trial of...